Michał Kawa

Michał Kawa

Auto-generated profile, based on publicly available information

Michał Kawa

Murcki Hospital in Katowice, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
GPGabriela Piotrowska
Gabriela Piotrowska
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
PKPaulina Kopcińska
Paulina Kopcińska
MMMagdalena Mortka
Magdalena Mortka
HBHubert Bednarz
Hubert Bednarz
WGWeronika Grzyb-Kurnik
Weronika Grzyb-Kurnik
Background:Obesity is a chronic, multifactorial disease with rapidly growing global prevalence. Bariatric surgery remains the most effective intervention for long-term weight reduction and improvement of obesity-related comorbidities; however, 16 - 37% of patients experience inadequate weight loss or weight regain, prompting the search for less invasive pharmacological strategies. Aim:To review the efficacy and safety of GLP-1 receptor agonists in adults after bariatric surgery presenting with insufficient weight loss or weight regain. Material and methods:A narrative literature review was conducted using medical databases and current guidelines, including original and review articles in English involving adult post-bariatric patients treated with GLP-1 receptor agonists, reporting weight-related outcomes and safety data. Results:Liraglutide 3.0 mg achieved additional weight loss of approximately 5 - 6% over 6 - 8 months, with early onset of effect and comparable efficacy across surgical techniques. Once-weekly semaglutide (0.5 mg) demonstrated weight loss of 10.3% at 6 months. After 12 months of GLP-1 receptor agonist therapy (liraglutide or semaglutide combined), median total body weight loss reached 11.2%. Preliminary data on tirzepatide suggest superior efficacy: 15.5% weight loss at 6 months versus 10.3% with semaglutide after sleeve gastrectomy. Adverse events were predominantly mild to moderate gastrointestinal symptoms. Conclusions:GLP-1 receptor agonists represent a promising, less invasive option for post-bariatric weight management and should be considered before revisional surgery in appropriately selected patients. Larger randomised studies - particularly with tirzepatide - are needed to define optimal drug choice, timing, and patient selection.

8 August 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
MKMichał Kawa
Michał Kawa
KIKamil Idzik
Kamil Idzik
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
PKPaulina Kopcińska
Paulina Kopcińska
GPGabriela Piotrowska
Gabriela Piotrowska
HBHubert Bednarz
Hubert Bednarz
Background: Caffeine is a well-established ergogenic aid that improves endurance performance at acute doses of 3–6 mg/kg. Widespread habitual intake, mainly via coffee, raises the question whether chronic exposure blunts this effect. Aim: To critically assess whether regular caffeine consumption, particularly habitual coffee intake, modifies the acute ergogenic response to pre-exercise caffeine in endurance contexts. Methods: A structured, non-exhaustive search (January 2020–June 2026) was performed in PubMed/MEDLINE, PubMed Central, Scopus, Web of Science, and the Cochrane Library, with citation tracking. Priority was given to systematic reviews, meta-analyses, randomized placebo-controlled crossover trials, and prospective studies on endurance performance, habitual intake, and acute responses; mechanistic papers were included selectively. Results: Acute caffeine consistently enhances endurance performance. The largest meta-analysis indicates no significant attenuation of the pooled ergogenic effect with habitual intake. However, longitudinal data suggest that repeated daily exposure may reduce the magnitude of benefit over time without abolishing it, consistent with partial, context-dependent habituation. Inter-individual variability is influenced by dose, timing, delivery form, and training status; genetic effects remain insufficiently defined for clinical personalization. Conclusions: Habitual caffeine use does not eliminate the ergogenic effect of acute supplementation in most endurance settings, but may attenuate responsiveness in some individuals. Evidence supports individualized strategies based on habitual intake, prior response, timing, and tolerability rather than routine abstinence or dose escalation. Well-controlled longitudinal studies are needed to clarify the extent and mechanisms of habituation.

8 August 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
GPGabriela Piotrowska
Gabriela Piotrowska
PKPaulina Kopcińska
Paulina Kopcińska
MMMagdalena Mortka
Magdalena Mortka
HBHubert Bednarz
Hubert Bednarz
WGWeronika Grzyb-Kurnik
Weronika Grzyb-Kurnik
Background: Psoriatic arthritis (PsA) and juvenile psoriatic arthritis (JPsA) are chronic inflammatory diseases with heterogeneous, multi-domain presentation; targeted therapies against TNF-alpha, IL-17 and the JAK-STAT pathway have expanded treatment options.Aim: To evaluate efficacy and safety of three classes of targeted therapies in PsA and JPsA: TNF-alpha inhibitors (TNF-i), IL-17 inhibitors (IL-17-i) and Janus kinase inhibitors (JAK-i).Material and methods: A narrative PubMed (MEDLINE) review of phase I-III randomized trials and open-label extensions, real-world studies, and selected reviews assessing efficacy and safety of TNF-i, IL-17-i and JAK-i in adults and children with PsA/JPsA.Results: Anti-TNF therapies show high ACR response rates, favourable skin effects, and inhibition of radiographic progression, with acceptable long-term safety. IL-17-i provide sustained improvement across major PsA domains, particularly in TNF-i-naive patients, with a stable safety profile. JAK-i are effective after failure of conventional and biologic treatment, improving joint activity, function and quality of life, but carry a characteristic adverse-event profile requiring assessment. Real-world analyses in PsA and axial spondyloarthritis show no significantly increased cardiovascular or malignancy risk with JAK-i versus anti-TNF/anti-IL-17 therapies, though rheumatoid arthritis data warrant caution in high-risk patients. In JPsA, TNF-i remain the principal biologic class, while anti-IL-17 trials confirm efficacy and safety in children.Conclusions: Targeted therapy of PsA and JPsA requires individualization based on phenotype, prior treatment, and cardiovascular, thromboembolic and oncologic risk. Further paediatric studies are needed to define each class's role in JPsA management.

6 September 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
MMMagdalena Mortka
Magdalena Mortka
HBHubert Bednarz
Hubert Bednarz
GPGabriela Piotrowska
Gabriela Piotrowska
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
PKPaulina Kopcińska
Paulina Kopcińska
MKMaja Kopyto
Maja Kopyto
Background: Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for major depressive disorder and anxiety disorders. Sexual dysfunction is among their most common adverse effects, impairing quality of life and treatment adherence. Increasing attention has focused on post-SSRI sexual dysfunction (PSSD), in which symptoms persist after antidepressant discontinuation. Objective: To summarize current evidence on sexual physiology, mechanisms and clinical features of antidepressant-induced sexual dysfunction (AISD) and PSSD, and available management strategies. Methods: A narrative review of English-language literature published between 2020 and 2026 was conducted using PubMed and Google Scholar. Original studies, systematic reviews, meta-analyses, randomized trials, observational studies, and relevant case reports were included, along with essential earlier landmark publications. Results: SSRI-associated sexual dysfunction may affect desire, arousal, erection, ejaculation, orgasm, and sexual satisfaction. Prevalence estimates vary because of differences in study populations and assessment methods. Symptoms usually improve after dose reduction or discontinuation, but may persist as PSSD. Proposed mechanisms include serotonergic dysregulation, altered dopaminergic and neuroendocrine signaling, epigenetic changes, TRP ion channel dysfunction, neurotoxicity, and gut–brain axis disturbances, although none has been confirmed. Management includes dose reduction, switching to antidepressants with a lower risk of sexual adverse effects, pharmacological augmentation, and selected non-pharmacological interventions. No evidence-based treatment for PSSD has been established. Conclusions: Sexual dysfunction is a major adverse effect of SSRI therapy. Routine assessment before and during treatment may facilitate recognition and management. High-quality prospective studies are needed to clarify the epidemiology, mechanisms, and optimal treatment of PSSD.

5 August 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
DGDominika Grzybowska
Dominika Grzybowska
MLMaria Leśniak
Maria Leśniak
HBHubert Bednarz
Hubert Bednarz
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
WGWeronika Grzyb-Kurnik
Weronika Grzyb-Kurnik
AUAleksander Urbaś
Aleksander Urbaś
Introduction and aim: Depression and anxiety disorders are leading causes of disability worldwide, and many patients respond inadequately to conventional treatment. The microbiota–gut–brain axis has emerged as a candidate contributor to their pathogenesis. This review aimed to synthesise mechanistic and clinical evidence linking gut microbiota, bacterial metabolites, and vagal signalling to depression and anxiety. Material and methods: A systematic search of PubMed, Embase, and Scopus (2011–2025) was performed following PRISMA principles, using terms for the gut–brain axis, microbiota, short-chain fatty acids, tryptophan, vagus nerve, depression, and anxiety. Studies were synthesised narratively across three mechanistic pillars. Results: Patients with depression and anxiety show reduced short-chain-fatty-acid-producing taxa and enrichment of pro-inflammatory bacteria. Bacterial metabolites—short-chain fatty acids, tryptophan catabolites, and gamma-aminobutyric acid—modulate neuroinflammation, blood–brain-barrier integrity, and neurotransmission. Several anxiolytic and antidepressant-like microbial effects are abolished by vagotomy, confirming a vagal route. Randomised trials of psychobiotics show small but significant reductions in depressive symptoms. Conclusions: The gut–brain axis is a biologically plausible, therapeutically tractable contributor to mood and anxiety disorders, though heterogeneity and causal uncertainty remain.

10 September 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
HBHubert Bednarz
Hubert Bednarz
MMMagdalena Mortka
Magdalena Mortka
GPGabriela Piotrowska
Gabriela Piotrowska
AGAgnieszka Anna Gaczoł
Agnieszka Anna Gaczoł
MKMaja Kopyto
Maja Kopyto
WGWeronika Grzyb-Kurnik
Weronika Grzyb-Kurnik
Background:Functional dyspepsia (FD) is a common disorder of gut–brain interaction and a major cause of chronic upper gastrointestinal symptoms and impaired quality of life. Current evidence challenges the traditional view of FD as solely a gastric motility disorder and indicates a multifactorial pathophysiology involving motor dysfunction, visceral hypersensitivity, duodenal immune activation, epithelial barrier impairment, gut microbiota alterations, and dysregulated gut–brain communication. Aim:To review current knowledge of the pathophysiology, clinical presentation, diagnosis, and evidence-based management of FD, with emphasis on emerging therapeutic targets and precision medicine. Material and methods:A narrative review was conducted using international clinical guidelines, systematic reviews, meta-analyses, randomized controlled trials, and translational studies concerning FD diagnosis, treatment, and recent advances in disease mechanisms. Results:FD is a heterogeneous disorder in which several overlapping biological mechanisms contribute to symptom generation. Diagnosis is primarily based on the Rome IV criteria after exclusion of structural disease. Established management includes lifestyle modification, Helicobacter pylori eradication, proton pump inhibitors, prokinetics, neuromodulators, and psychological therapies. Emerging approaches targeting the duodenal microenvironment, epithelial barrier, gut microbiota, and gut–brain axis are promising. Nevertheless, treatment efficacy remains modest because of biological heterogeneity and the lack of validated biomarkers for patient stratification. Conclusions:The evolving understanding of FD supports a shift from empirical symptom-based treatment toward individualized, mechanism-informed care. Future research should focus on clinically applicable biomarkers, improved phenotyping, and high-quality clinical trials to enable precision medicine and improve long-term outcomes.